Trials / Completed
CompletedNCT04507282
Eosinophil and Anticoagulation in COVID-19 Patients
Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (actual)
- Sponsor
- Bursa Postgraduate Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LMWH | COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level |
Timeline
- Start date
- 2020-05-15
- Primary completion
- 2020-07-01
- Completion
- 2020-07-15
- First posted
- 2020-08-11
- Last updated
- 2020-08-18
Locations
1 site across 1 country: Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04507282. Inclusion in this directory is not an endorsement.